A small study found MS patients reported improved quality of life and reduced depression after Ocrelizumab biosimilar treatment ...

In multiple sclerosis (MS), a person's immune system attacks the protective covering (myelin sheath) of nerve fibers in the brain and spinal cord (central nervous system). MS disease-modifying ...

Even women with more severe MS cases are less likely than men to get critical treatments, a new study finds. Women under age 40 with multiple sclerosis are 8 percent less likely than men to receive ...

For decades, multiple sclerosis (MS) has been defined primarily by its symptoms, rather than its underlying biology. Now, a ...

Injectable medications for multiple sclerosis (MS) are known as disease-modifying therapies (DMTs). This means they work by slowing or changing the progression of the condition. These are ...

MS is a chronic, immune-mediated disease affecting the central nervous system, with no known cure and varying levels of impact on individuals. Over 20 FDA-approved disease-modifying therapies exist, ...

Value-based agreements come with risks and benefits, but a health system’s existing facilities and initiatives can help support the goals associated with them, JT Lew, PharmD, MBA, a managed care ...

People with multiple sclerosis appear to have higher rates of thyroid problems than the general population. The link isn’t clear, but shared pathways and MS medication side effects may play a role. MS ...

The researchers observed an increase in OOP costs for multiple sclerosis medications, by an average of 217%. (HealthDay News) — Generic medications reduce the out-of-pocket (OOP) costs for common ...

Many women with multiple sclerosis (MS) notice a worsening of symptoms or progression just as menopause begins. While getting older is linked with disease progression in both men and women, hormones ...